"The main agent used is ferumoxytol (Feraheme), an ultrasmall SPIO, which is otherwise used to treat iron deficiency anaemia in patients with chronic kidney disease. Knowledge of this other use is important as administration of ferumoxytol (within 3 months) can complicate MRI interpretation, manifesting as susceptibility artifact, pre-gadolinium contrast T1 hyperintensity, and T2 hypointensity in the vasculature 1,2."
"The main agent used is ferumoxytol (Feraheme), an ultrasmall SPIO, which is otherwise used to treat iron deficiency anaemia in patients with chronic kidney disease. Knowledge of this other use is important as administration of ferumoxytol (within 3 months) can complicate MRI interpretation, manifesting as susceptibility artifact, pre-gadolinium contrast T1 hyperintensity, and T2 hypointensity in the vasculature 1,2."
"Previously available SPIO agents for MRI include:"
Expected headings
"Biodistribution"